| Literature DB >> 29534019 |
Ilzira A Minigalieva1, Boris A Katsnelson2, Larisa I Privalova3, Marina P Sutunkova4, Vladimir B Gurvich5, Vladimir Y Shur6, Ekaterina V Shishkina7, Irene E Valamina8, Oleg H Makeyev9, Vladimir G Panov10, Anatoly N Varaksin11, Tatiana V Bushueva12, Renata R Sakhautdinova13, Svetlana V Klinova14, Svetlana N Solovyeva15, Ekaterina Y Meshtcheryakova16.
Abstract
Stable suspensions of metal/metalloid oxide nanoparticles (MeO-NPs) obtained by laser ablation of 99.99% pure elemental aluminum, titanium or silicon under a layer of deionized water were used separately, or in three binary combinations, or in a ternary combination to induce subchronic intoxications in rats. To this end, the MeO-NPs were repeatedly injected intraperitoneally (i.p.) 18 times during 6 weeks before measuring a large number of functional, biochemical, morphological and cytological indices for the organism's status. In many respects, the Al₂O₃-NP was found to be the most toxic species alone and the most dangerous component of the combinations studied. Mathematical modeling with the help of the Response Surface Methodology showed that, as well as in the case of any other binary toxic combinations previously investigated by us, the organism's response to a simultaneous exposure to any two of the MeO-NP species under study was characterized by a complex interaction between all possible types of combined toxicity (additivity, subadditivity or superadditivity of unidirectional action and different variants of opposite effects) depending on which outcome this type was estimated for and on effect and dose levels. With any third MeO-NP species acting in the background, the type of combined toxicity displayed by the other two remained virtually the same or changed significantly, becoming either more or less unfavorable. Various harmful effects produced by the (Al₂O₃-NP + TiO₂-NP + SiO₂-NP)-combination, including its genotoxicity, were substantially attenuated by giving the rats per os during the entire exposure period a complex of innocuous bioactive substances expected to increase the organism's antitoxic resistance.Entities:
Keywords: bioprotectors; comparative and combined toxicity; nanoparticles; subchronic effects
Mesh:
Substances:
Year: 2018 PMID: 29534019 PMCID: PMC5877698 DOI: 10.3390/ijms19030837
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Averaged Elemental Composition of the Aerosol Particles Collected on Filters from the Workspace Air of Aluminum-Titanium Alloy Production Facilities (expressed in % of Total Elements Less Carbon and Oxygen).
| Element | Percentage Content |
|---|---|
| As | 0.1 |
| Ca | 8.2 |
| Cl | 5.6 |
| Cr | 2.5 |
| Cu | 0.1 |
| F | 1.1 |
| Fe | 2.9 |
| K | 3.8 |
| Mg | 11.4 |
| Na | 6.7 |
| Pb | 4.0 |
| S | 3.6 |
| Sn | 0.5 |
| Zn | 5.2 |
| Total | 100 |
Functional and Biochemical Indices of Rat Organism Status differing significantly from controls and/or those of other groups after 18 (during 6 Weeks) Intraperitoneal Injections of Suspensions of Various MeO-NP Species Administered Individually in Binary Combinations (x ± s.e.). The complete Table is given as Table S1 of Supporting Material; x, mean; s.e., standard error.
| Index | Control | Al2O3 | TiO2 | SiO2 | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 |
|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | ||
| Number of head-dips into holes during 3 min | 4.73 ± 0.94 | 2.64 ± 0.64 * | 1.92 ± 0.36 * | 2.82 ± 0.64 | 5.08 ± 1.02 2 | 3.00 ± 0.59 | 4.42 ± 0.67 2 |
| Number of squares crossed during 3 min | 8.18 ± 1.25 | 5.82 ± 1.09 | 5.67 ± 0.99 | 7.00 ± 0.86 | 7.58 ± 1.17 | 5.00 ± 0.55 * | 7.58 ± 1.19 |
| Left kidney mass, g/100 g body mass | 0.30 ± 0.01 | 0.28 ± 0.01 | 0.30 ± 0.01 1 | 0.30 ± 0.01 1 | 0.30 ± 0.01 1 | 0.29 ± 0.01 | 0.30 ± 0.01 |
| Right kidney mass, g/100 g body mass | 0.31 ± 0.01 | 0.28 ± 0.01 * | 0.30 ± 0.01 1 | 0.30 ± 0.01 1 | 0.30 ± 0.01 1 | 0.30 ± 0.01 1 | 0.30 ± 0.01 |
| Spleen mass, g/100 g body mass | 0.17 ± 0.01 | 0.20 ± 0.01 | 0.17 ± 0.01 1 | 0.19 ± 0.01 | 0.18 ± 0.01 | 0.17 ± 0.01 1,3 | 0.18 ± 0.01 |
| Right testicle mass, g/100 g body mass | 0.55 ± 0.02 | 0.51 ± 0.01 | 0.52 ± 0.02 | 0.55 ± 0.01 1 | 0.54 ± 0.01 | 0.55 ± 0.01 1 | 0.53 ± 0.01 |
| Brain mass, g/100 g body mass | 0.62 ± 0.01 | 0.59 ± 0.01 * | 0.58 ± 0.02 * | 0.63 ± 0.01 1,2 | 0.61 ± 0.01 | 0.61 ± 0.01 | 0.61 ± 0.01 |
| Hemoglobin, g/L | 158.89 ± 1.16 | 141.14 ± 1.99 * | 149.00 ± 3.64 1, * | 149.71 ± 2.74 1, * | 147.33 ± 2.87 * | 146.00 ± 1.51 * | 151.25 ± 2.45 * |
| Erythrocytes, 1012 cells/L | 7.93 ± 0.16 | 7.68 ± 0.32 | 7.23 ± 0.13 * | 7.58 ± 0.14 | 7.61 ± 0.24 | 7.48 ± 0.11 * | 7.52 ± 0.10 * |
| Average erythrocyte volume, µm3 | 54.69 ± 0.86 | 55.05 ± 0.87 | 54.29 ± 0.85 | 54.34 ± 0.51 | 52.17 ± 0.67 1,2, * | 52.36 ± 0.57 1,3, * | 54.94 ± 0.34 |
| Reticulocytes, ‰ | 13.63 ± 1.65 | 25.64 ± 2.32 * | 32.60 ± 3.01 * | 26.63 ± 1.66 * | 29.90 ± 1.28 * | 25.86 ± 1.61 * | 31.67 ± 2.73 * |
| Hematocrit, % | 21.54 ± 0.21 | 19.73 ± 0.26 * | 20.21 ± 0.52 * | 20.60 ± 0.40 * | 20.03 ± 0.69 * | 19.59 ± 0.26 * | 20.65 ± 0.28 * |
| Leukocytes, 103/µL | 7.20 ± 0.37 | 8.98 ± 0.86 * | 8.40 ± 0.43 * | 7.69 ± 0.67 | 9.10 ± 1.03 | 9.40 ± 0.83 * | 7.85 ± 0.67 |
| Banded neutrophils, % | 1.50 ± 0.17 | 1.88 ± 0.30 | 0.88 ± 0.13 1 * | 1.88 ± 0.40 2 | 1.00 ± 0.00 1, * | 2.29 ± 0.29 * | 1.38 ± 0.18 2 |
| Succinate dehydrogenase (SDH) in blood lymphocytes, number of formazan granules per 50 cells | 589.45 ± 16.55 | 536.73 ± 17.43 * | 539.36 ± 16.94 * | 553.55 ± 17.46 | 562.67 ± 15.74 | 551.55 ± 20.54 | 530.42 ± 16.03 * |
| γ-glutamyl transpeptidase (GGTP), IU/L | 2.26 ± 0.69 | 1.14 ± 0.38 | 1.14 ± 0.40 | 1.86 ± 0.69 | 2.48 ± 0.45 1,2 | 3.98 ± 0.99 1 | 0.74 ± 0.30 |
| Glucose, mol/L | 7.09 ± 0.26 | 6.80 ± 0.21 | 6.33 ± 0.25 * | 6.80 ± 0.30 | 6.10 ± 0.30 * | 6.64 ± 0.18 | 7.04 ± 0.29 |
| Ceruloplasmin in blood serum, mg per 100 mL | 33.14 ± 1.13 | 38.09 ± 1.56 * | 42.03 ± 2.05 * | 40.39 ± 1.50 * | 44.06 ± 1.53 1, * | 46.22 ± 2.35 1,3, * | 42.88 ± 1.44 * |
| Malonyl dialdehyde (MDA) in blood serum, µmol/L | 3.51 ± 0.49 | 3.99 ± 0.19 | 3.16 ± 0.28 1 | 3.37 ± 0.31 | 3.56 ± 0.48 | 5.10 ± 0.37 1,3, * | 4.57 ± 0.19 2,3, * |
| Catalase in blood serum, µmol/L | 1.34 ± 0.25 | 1.30 ± 0.22 | 1.20 ± 0.27 | 1.12 ± 0.22 | 1.31 ± 0.22 | 1.18 ± 0.24 | 0.65 ± 0.12 * |
| Total protein content of blood serum, g/L | 80.47 ± 1.42 | 76.81 ± 1.97 | 75.43 ± 1.40 * | 75.36 ± 2.00 * | 80.49 ± 2.01 | 78.20 ± 1.33 | 78.93 ± 2.15 |
| Albumin content of blood serum, g/L | 44.34 ± 0.61 | 39.49 ± 0.81 * | 40.28 ± 1.35 * | 40.25 ± 1.44 * | 41.31 ± 1.05 * | 39.58 ± 0.67 * | 40.18 ± 1.24 * |
| Albumin/Globulin Ratio | 1.24 ± 0.04 | 1.08 ± 0.06 * | 1.17 ± 0.07 | 1.14 ± 0.06 | 1.06 ± 0.05 * | 1.03 ± 0.03 * | 1.05 ± 0.05 * |
| ALT activity in blood serum, IU/L | 70.82 ± 3.24 | 72.70 ± 3.10 | 69.00 ± 4.19 | 58.55 ± 4.281 * | 66.46 ± 4.41 | 66.50 ± 1.66 | 63.94 ± 3.32 |
| Alkaline phosphatase, IU/L | 193.64 ± 13.08 | 215.71 ± 14.74 | 216.61 ± 23.36 | 212.59 ± 26.36 | 222.55 ± 13.71 | 240.48 ± 21.89 * | 236.53 ± 10.62 * |
| Creatinine in blood serum, µmol/L | 36.33 ± 1.46 | 33.64 ± 1.09 | 30.80 ± 0.711 * | 32.40 ± 1.29 * | 34.46 ± 1.71 | 34.50 ± 1.49 | 33.89 ± 1.352 |
| Concentration of Ca2+ in blood serum, mol/L | 2.61 ± 0.03 | 2.53 ± 0.02 * | 2.54 ± 0.05 | 2.55 ± 0.04 | 2.56 ± 0.04 | 2.57 ± 0.03 | 2.52 ± 0.05 |
| Urea in blood serum, mmol/L | 4.44 ± 0.34 | 3.69 ± 0.28 | 3.89 ± 0.45 | 3.29 ± 0.40 * | 3.59 ± 0.36 | 3.71 ± 0.27 | 3.73 ± 0.37 |
| Daily diuresis, mL | 29.67 ± 4.36 | 21.17 ± 2.39 | 26.43 ± 3.88 | 28.43 ± 5.73 | 33.00 ± 2.50 1 | 24.86 ± 2.20 | 31.71 ± 5.64 |
| Creatinine in urine, mmol/L | 1.57 ± 0.11 | 2.56 ± 0.27 * | 2.15 ± 0.35 | 1.91 ± 0.161 | 1.54 ± 0.141 | 1.92 ± 0.131 | 1.85 ± 0.17 |
| Protein in urine, g/L | 190.43 ± 29.63 | 298.45 ± 32.35 * | 216.55 ± 33.41 | 180.93 ± 17.09 1 | 196.13 ± 20.43 1 | 193.36 ± 20.67 1 | 211.45 ± 37.18 |
| Urine pH | 7.17 ± 0.17 | 6.50 ± 0.26 * | 7.33 ± 0.40 | 7.36 ± 0.30 | 6.79 ± 0.15 | 7.00 ± 0.29 | 6.93 ± 0.17 |
| Urea in urine, mmol/L | 229.30 ± 16.00 | 319.41 ± 29.85 * | 278.06 ± 46.97 | 240.15 ± 25.77 1 | 211.22 ± 17.47 1 | 262.08 ± 19.23 | 238.15 ± 24.71 |
The asterisk * designates the values which are statistically significantly different from the respective control ones, and the superscript numbers those statistically significantly different from the corresponding groups denoted with a corresponding number (p < 0.05 by ANOVA test).
Functional and Biochemical Indices of Rat Organism Status differing significantly from controls and/or those of other groups after 18 (during 6 Weeks) Intraperitoneal Injections of Suspensions of Various МеO-NP Species Administered in Binary or Ternary Combinations (x ± s.e.). The complete Table is given as Table S2 of Supporting Materials.
| Index | Control | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 | Al2O3 + SiO2+ TiO2 | Al2O3 + SiO2 + TiO2 and BPC | BPC |
|---|---|---|---|---|---|---|---|
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | ||
| Body mass gain, % | 15.13 ± 1.85 | 13.41 ± 2.07 | 14.70 ± 1.86 | 12.58 ± 2.09 | 15.40 ± 2.02 | 18.34 ± 2.00 | 20.32 ± 1.41 * |
| Number of squares crossed during 3 min | 8.18 ± 1.25 | 7.58 ± 1.17 | 5.00 ± 0.55 * | 7.58 ± 1.19 | 6.50 ± 1.09 | 4.90 ± 1.14 | 7.78 ± 1.16 |
| Brain mass, g/100 g body mass | 0.62 ± 0.01 | 0.61 ± 0.01 | 0.61 ± 0.01 | 0.61 ± 0.01 | 0.59 ± 0.01 * | 0.59 ± 0.01 * | 0.61 ± 0.01 |
| Hemoglobin, g/L | 158.89 ± 1.16 | 147.33 ± 2.87 * | 146.00 ± 1.51 * | 151.25 ± 2.45 * | 147.75 ± 2.28 * | 143.26 ± 1.49 * | 151.14 ± 1.92 * |
| Erythrocytes, 1012 cells/L | 7.93 ± 0.16 | 7.61 ± 0.24 | 7.48 ± 0.11 * | 7.52 ± 0.10 * | 7.83 ± 0.17 | 7.75 ± 0.14 | 7.42 ± 0.10 * |
| Average erythrocyte volume, µm3 | 54.69 ± 0.86 | 52.17 ± 0.67 * | 52.36 ± 0.57 * | 54.94 ± 0.34 | 51.73 ± 0.93 * | 51.88 ± 0.82 * | 56.60 ± 0.61 |
| Reticulocytes, ‰ | 13.63 ± 1.65 | 29.90 ± 1.28 * | 25.86 ± 1.61 * | 31.67 ± 2.73 * | no data | 26.00 ± 0.88 * | 17.67 ± 4.78 |
| Hematocrit, % | 21.54 ± 0.21 | 20.03 ± 0.69 * | 19.59 ± 0.26 * | 20.65 ± 0.28 * | 20.20 ± 0.30 * | 20.09 ± 0.45 * | 21.00 ± 0.36 |
| Thrombocytes,103/µL | 847.25 ± 25.41 | 831.75 ± 54.09 | 926.57 ± 27.89 | 880.50 ± 34.53 | 882.25 ± 36.87 | 979.56 ± 26.63 4, * | 890.25 ± 36.39 |
| Thrombocrit, % | 0.23 ± 0.02 | 0.24 ± 0.02 | 0.27 ± 0.01 | 0.25 ± 0.01 | 0.26 ± 0.01 | 0.29 ± 0.01 4, * | 0.27 ± 0.01 |
| Leukocytes, 103/µL | 7.20 ± 0.37 | 9.10 ± 1.03 | 9.40 ± 0.83 * | 7.85 ± 0.67 | 7.78 ± 0.66 | 10.04 ± 0.93 4, * | 7.88 ± 0.46 |
| Eosinophils % | 2.20 ± 0.29 | 3.13 ± 0.48 | 3.57 ± 0.87 | 2.13 ± 0.40 | 3.00 ± 0.42 | 3.22 ± 0.36 * | 3.13 ± 0.69 |
| Banded neutrophils, % | 1.50 ± 0.17 | 1.00 ± 0.00 * | 2.29 ± 0.29 * | 1.38 ± 0.18 | 1.63 ± 0.26 | 1.67 ± 0.33 | 1.25 ± 0.16 |
| Succinate dehydrogenase (SDH) in blood lymphocytes, number of formazan granules per 50 cells | 589.45 ± 16.55 | 562.67 ± 15.74 | 551.55 ± 20.54 | 530.42 ± 16.03 * | 561.64 ± 15.99 | 559.50 ± 16.67 | 578.90 ± 14.48 |
| Ceruloplasmin in blood serum, mg per 100 mL | 33.14 ± 1.13 | 44.06 ± 1.53 * | 46.22 ± 2.35 * | 42.88 ± 1.44 * | 42.61 ± 1.88 * | 38.36 ± 2.71 | 30.54 ± 1.82 |
| Malonyl dialdehyde (MDA) in blood serum, µmol/L | 3.51 ± 0.49 | 3.56 ± 0.48 | 5.10 ± 0.37 * | 4.57 ± 0.19 * | 4.28 ± 0.29 | 4.20 ± 0.28 | 4.09 ± 0.19 |
| Catalase in blood serum, µmol/L | 1.34 ± 0.25 | 1.31 ± 0.22 | 1.18 ± 0.24 | 0.65 ± 0.12 * | 1.10 ± 0.21 | 0.74 ± 0.25 | 0.86 ± 0.31 |
| Reduced glutathione in whole blood, µmol/L | 26.82 ± 1.19 | 26.20 ± 0.87 | 28.44 ± 1.473 | 26.00 ± 1.39 | 22.55 ± 1.41 * | 26.39 ± 1.36 4 | 28.17 ± 1.35 |
| Albumin content of blood serum, g/L | 44.34 ± 0.61 | 41.31 ± 1.05 * | 39.58 ± 0.67 * | 40.18 ± 1.24 * | 41.91 ± 0.88 * | 43.38 ± 0.94 | 44.91 ± 0.90 |
| Albumin/Globulin Ratio | 1.24 ± 0.04 | 1.06 ± 0.05 * | 1.03 ± 0.03 * | 1.05 ± 0.05 * | 1.11 ± 0.04 * | 1.17 ± 0.05 | 1.27 ± 0.05 |
| ALT activity in blood serum, IU/L | 70.82 ± 3.24 | 66.46 ± 4.41 | 66.50 ± 1.66 | 63.94 ± 3.32 | 66.75 ± 3.55 | 83.09 ± 5.13 4, * | 84.98 ± 4.69 * |
| Alkaline phosphatase, IU/L | 193.64 ± 13.08 | 222.55 ± 13.71 | 240.48 ± 21.89 * | 236.53 ± 10.62 * | 200.30 ± 12.15 | 209.78 ± 21.48 | 261.99 ± 24.46 * |
| Urea in blood serum, mmol/L | 4.44 ± 0.34 | 3.59 ± 0.36 | 3.71 ± 0.27 | 3.73 ± 0.37 | 3.35 ± 0.42 | 4.93 ± 0.45 4 | 4.49 ± 0.42 |
| Creatinine in urine, mmol/L | 1.57 ± 0.11 | 1.54 ± 0.14 | 1.92 ± 0.13 | 1.85 ± 0.17 | 2.03 ± 0.19 * | 1.74 ± 0.25 | 1.43 ± 0.21 |
| Protein in urine, g/L | 190.43 ± 29.63 | 196.13 ± 20.43 | 193.36 ± 20.67 | 211.45 ± 37.18 | 233.13 ± 30.83 | 354.33 ± 66.07 | 243.93 ± 22.83 * |
The asterisk * designates the values which are statistically significantly different from the control ones, and the superscript numbers mark the values which are statistically significantly different from the corresponding values of the groups denoted with a corresponding number (p < 0.05 by ANOVA test).
Figure 1Combined subchronic toxicity isobolograms assessed by an increase in the concentration of ceruloplasmin in blood serum under exposure to (a) SiO2-NP + TiO2-NP (subadditivity); (b) SiO2-NP + Al2O3-NP (additivity); (c) TiO2-NP + Al2O3-NP (insignificant subadditivity). The axes represent doses of corresponding MeO-NPs in mg per rat; the numbers at the isoboles denote the magnitude of the effect (in mg per 100 mL). Note that the RSM-model (Response Surface Method) failed to reveal for this effect even the above-mentioned tendency towards superadditivity.
Figure 2Combined subchronic toxicity isobolograms assessed by an increase in the concentration of AST in blood serum under exposure to (а) SiO2-NP + TiO2-NP (opposite action); (b) SiO2-NP + Al2O3-NP (opposite action); (c) TiO2-NP + Al2O3-NP (subadditivity of unidirectional action). The axes represent doses of corresponding MeO-NPs in mg per rat; the numbers at the isoboles denote the magnitude of the effect (in IU/L).
Figure 3The ambiguity of the TiO2-NP + Al2O3-NP combined subchronic toxicity type assessed by a decrease in the GGTP content of blood serum: subadditivity of unidirectional action at low doses and relatively high levels of effect; superadditivity at high doses and similar levels of effect; opposite action at low doses and relatively low levels of effect and also at high doses and relatively low doses of effect. The axes represent doses of corresponding МеО-NPs in mg per rat; the numbers at the isoboles denote the magnitude of the effect (in IU/L).
Figure 4An example of three-factor toxicity falling into class “A”: (а) a subadditive or opposite action (for different levels of effect and doses) of the combination (Al2O3-NP + TiO2-NP) in the absence of a third factor on the creatinine content of blood serum transforms (for all effect levels and doses) into (b) an additive one in the presence of simultaneously influencing SiO2-NPs. Mе-NP doses are plotted on the axes in mg per rat. The numbers at the lines correspond to the magnitude of the effect (µmol/L).
Morphometric Indices of Damage to the Epithelium of the Proximal Convoluted Tubules in Rat Kidneys after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Index | Group Exposed i.p. to МеО-NP | ||||||
|---|---|---|---|---|---|---|---|
| Control | Al2O3 | TiO2 | SiO2 | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 | |
| Brush border loss, % | 1.49 ± 0.56 | 1.85 ± 0.47 | 3.61 ± 0.99 * | 2.24 ± 0.58 | 6.45 ± 1.07 *, x, @ | 4.23 ± 0.80 *, +, @ | 3.64 ± 0.70 * |
| Epithelial desquamation, % | 0.00 ± 0.00 | 0.15 ± 0.15 | 0.42 ± 0.36 | 0.30 ± 0.25 | 0.97 ± 0.48 * | 0.29 ± 0.17 | 0.14 ± 0.14 |
Statistically significant (p < 0.05 by ANOVA test) difference: * from the control value, + from the value of the SiO2 group, х from the value of the ТiO2 group, @ from the value of the Al2O3 group.
Figure 5The kinetics of nanoparticle dissolution in suspension upon addition of FBS. Circles correspond to actual measurements at different time points during first 300 min, the red lines—to their approximation by exponential equations of the general formula: A + B exp(−t/τ) extrapolated to the 750 min.
Morphometric Indices of Damage to the Epithelium of the Proximal Convoluted Tubules in Rat Kidneys after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP in Binary or Ternary Combinations (x ± s.e.).
| Index | Group Receiving i.p. МеО-NP | ||||||
|---|---|---|---|---|---|---|---|
| Control | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 | Al2O3 + TiO2 + SiO2 at Half Dose | Al2O3 + TiO2 + SiO2 in Full Doses | Al2O3 + TiO2 + SiO2 in Full Doses with BPC | |
| Brush border loss, % | 1.49 ± 0.56 | 6.45 ± 1.07 * | 4.23 ± 0.80 * | 3.64 ± 0.70 *, # | 3.06 ± 0.84 # | 7.19 ± 1.47 * | 1.99 ± 0.43 # |
| Epithelial desquamation, % | 0.00 ± 0.00 | 0.97 ± 0.48 * | 0.29 ± 0.17 | 0.14 ± 0.14 | 0.66 ± 0.47 | 1.04 ± 0.39 * | 0.18 ± 0.16 # |
Statistically significant (p < 0.05 by ANOVA test) difference * from control value, # from the value of the group administered the ternary combination in full dose without BPC.
Figure 6Isobolograms of combined subchronic toxicity assessed by brush border loss in the epithelium of renal tubules: (а) SiO2-NP + TiO2-NP (single-factor effect of TiO2-NP with insignificant additivity); (b) SiO2-NP + Al2O3-NP (additivity tending towards synergism); (c) TiO2-NP + Al2O3-NP (the same type of action). The axes represent doses of corresponding МеО-NPs in mg per rat. The numbers at the isoboles denote the magnitude of the effect (expressed in %—see the text).
Figure 7Isoboles of combined subchronic toxicity of Al2O3-NP + TiO2-NP assessed by epithelial desquamation of renal tubules: (a) additivity of unidirectional action in the absence of a third MeО-NP; (b) superadditivity in the presence of SiO2-NP (an example of a three-factor action falling within class А). The axes represent doses of corresponding МеО-NPs in mg per rat; the numbers at the isoboles denote the magnitude of the effect (expressed in %).
Morphometric Indices of Liver Status in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Number of Cells of a Given Type per 100 Liver Cells | Group Receiving i.p. МеО-NP | ||||||
|---|---|---|---|---|---|---|---|
| Control | Al2O3 | TiO2 | SiO2 | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 | |
| Acaryotic hepatocytes | 10.30 ± 1.09 | 17.60 ± 0.98 * | 41.27 ± 1.36 * | 39.67 ± 2.58 * | 29.45 ± 1.47 * | 41.88 ± 1.72 * | 41.90 ± 1.48 * |
| Binucleated hepatocytes | 6.65 ± 0.83 | 5.67 ± 0.55 | 4.13 ± 0.47 * | 3.27 ± 0.46 * | 5.13 ± 0.46 | 3.13 ± 0.37 * | 3.75 ± 0.52 * |
| Kupffer cells | 14.28 ± 0.45 | 18.07 ± 0.62 * | 21.43 ± 0.68 * | 21.03 ± 0.62 * | 19.58 ± 0.60 * | 18.80 ± 0.72 * | 21.05 ± 0.53 * |
The sign * denotes a statistically significant (p < 0.05 by ANOVA test) difference from the corresponding control value. Also, there is a statistically significant difference: (1) in all indices, between the group exposed to Al2O3-NP and the group of individual exposure to the other two МеО-NPs; (2) in the number of akaryotic hepatocytes, between the group exposed to (Al2O3-NP + TiO2-NP) and the groups of exposure to both components individually; between the group exposed to (Al2O3-NP + SiO2-NP) and the group of exposure to Al2O3-NP alone; between the group exposed to (Al2O3-NP + ТiO2-NP) and the group of exposure to Al2O3-NP alone; (3) in the number of binucleated hepatocytes, between the group exposed to (Al2O3-NP + SiO2-NP) and the group of exposure to Al2O3-NP alone; (4) in the number of Kupffer cells, between the group exposed to (Al2O3-NP + ТiO2-NP) and the group of exposure to TiO2-NP alone; between the group exposed to (Al2O3-NP + SiO2-NP) and the group of exposure to SiO2-NP alone.
Morphometric Indices of Liver and Spleen Status in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP in Binary or Ternary Combination (x ± s.e.).
| Morphometric Index | Group Receiving i.p. МеО-NP | ||||||
|---|---|---|---|---|---|---|---|
| Control | Al2O3 + TiO2 | Al2O3 + SiO2 | TiO2 + SiO2 | Al2O3 + TiO2 + SiO2 at Half Dose | Al2O3 + TiO2 + SiO2 B in Full Dose | Al2O3 + TiO2 + SiO2 in Full Dose with BPC | |
| Akaryotic hepatocytes | 10.30 ± 1.09 | 29.45 ± 1.47 * | 41.88 ± 1.72 *, # | 41.90 ± 1.48 *, # | 16.92 ± 0.81 *, # | 31.85 ± 1.74 * | 27.13 ± 1.20 *, # |
| Binucleated hepatocytes | 6.65 ± 0.83 | 5.13 ± 0.46 | 3.13 ± 0.37 * | 3.75 ± 0.52 * | 5.00 ± 0.33 * | 4.05 ± 0.78 * | 3.35 ± 0.32 * |
| Kupffer cells | 14.28 ± 0.45 | 19.58 ± 0.60 * | 18.80 ± 0.72 * | 21.05 ± 0.53 * | 20.58 ± 0.48 * | 20.08 ± 0.75 * | 18.58 ± 0.53 * |
| White pulp to red pulp planimetric ratio | 0.50 ± 0.03 | 0.62 ± 0.05 *, #, @ | 0.63 ± 0.04 *, #, @ | 0.75 ± 0.05 *, #, @ | 0.92 ± 0.06 * | 0.95 ± 0.06 * | 0.47 ± 0.04 #, @ |
The sign * denotes a statistically significant (p < 0.05 by ANOVA test) difference from control value, # from the index of the group administered the ternary combination in full dose without BPC; @ from the group administered the ternary combination at half dose without BPC.
Figure 8Isobolograms of combined subchronic toxicity of SiO2-NP + TiO2-NP assessed by an increase in the number of Kupffer cells: (a) subadditivity of unidirectional action in the absence of a third MeО-NP; (b) additivity in the presence of Al2O3-NP (an example of three-factor effect falling within class А). The axes represent doses of corresponding МеО-NPs in mg per rat; the numbers at the isoboles denote the magnitude of the effect (expressed in %—see the text).
Some Cytological Characteristics of Rat Liver Tissue Imprints as a Percentage of Total Cell Count in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Factor | Duct Epithelial Cells | Degenerated Hepatocytes | Binucleated Hepatocytes | Kupffer Cells | Neutrophils | Eosinophils |
|---|---|---|---|---|---|---|
| Al2О3-NP | 10.51 ± 1.79 | 9.49 ± 1.71 | 0.68 ± 0.48 | 6.10 ± 1.39 * | 10.17 ± 1.76 * | 3.73 ± 1.10 |
| TiО2-NP | 9.52 ± 1.71 * | 8.16 ± 1.60 | 0.68 ± 0.48 | 2.38 ± 0.89 | 8.50 ± 1.63 * | 5.10 ± 1.28 * |
| SiО2-NP | 14.29 ± 2.04 | 5.78 ± 1.36 | 1.36 ± 0.68 | 3.74 ± 1.11 | 8.16 ± 1.60 * | 5.10 ± 1.28 * |
| Al2О3-NP + TiО2-NP | 12.71 ± 1.95 | 11.34 ± 1.86 * | 1.03 ± 0.59 | 4.81 ± 1.25 | 5.84 ± 1.37 | 2.06 ± 0.83 |
| Al2О3 + SiО2-NP | 11.90 ± 1.89 | 8.16 ± 1.60 | 1.02 ± 0.59 | 5.44 ± 1.32 * | 6.80 ± 1.47 | 5.10 ± 1.28 * |
| TiО2 + SiО2-NP | 11.41 ± 1.84 | 9.73 ± 1.72 | 0.67 ± 0.47 | 4.36 ± 1.18 | 9.73 ± 1.72 * | 4.36 ± 1.18 * |
| Control | 14.86 ± 2.07 | 6.42 ± 1.42 | 1.01 ± 0.58 | 2.03 ± 0.82 | 3.72 ± 1.10 | 1.35 ± 0.67 |
The asterisk * denotes values which are statistically significantly different from the control (p < 0.05 by ANOVA test).
Some Cytological Characteristics of Kidney Tissue Imprints as a Percentage of Total Cell Count in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Factor | Proximal Tubule Cells | Degenerated Cells of Proximal Tubules | Distal Tubule Cells | Degenerated Cells of Distal Tubules | Neutrophils | Eosinophils |
|---|---|---|---|---|---|---|
| Al2О3-NP | 60.33 ± 2.82 | 13.00 ± 1.94 | 7.00 ± 1.47 | 8.33 ± 1.60 | 4.33 ± 1.18 | 2.33 ± 0.87 |
| TiО2-NP | 56.00 ± 2.87 * | 14.00 ± 2.00 | 7.67 ± 1.54 | 8.33 ± 1.60 | 5.00 ± 1.26 | 5.00 ± 1.26 * |
| SiО2-NP | 56.67 ± 2.86 * | 14.67 ± 2.04 | 9.00 ± 1.65 | 6.00 ± 1.37 | 5.67 ± 1.33 | 2.00 ± 0.81 |
| Al2О3-NP + TiО2-NP | 58.67 ± 2.84 * | 16.33 ± 2.13 * | 8.00 ± 1.57 | 5.67 ± 1.33 | 4.00 ± 1.13 | 2.67 ± 0.93 |
| Al2О3 + SiО2-NP | 56.67 ± 2.86 * | 16.00 ± 2.12 * | 7.00 ± 1.47 | 9.00 ± 1.65 | 4.00 ± 1.13 | 2.67 ± 0.93 |
| TiО2 + SiО2-NP | 57.48 ± 2.85 * | 14.29 ± 2.02 | 9.30 ± 1.67 | 7.64 ± 1.53 | 4.65 ± 1.21 | 1.66 ± 0.74 + |
| Control | 67.67 ± 2.70 | 10.00 ± 1.73 | 7.67 ± 1.54 | 5.00 ± 1.26 | 5.00 ± 1.26 | 0.67 ± 0.47 |
The asterisk * denotes values which are statistically significantly different from the control; the sign + denotes the difference from the group administered TiО2-NP alone (p < 0.05 by ANOVA test).
Some Cytological Characteristics of Mesenteric Tissue Imprints as a Percentage of Total Cell Count in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Factor | Mature Lymphocytes and Prolymphocytes | Lymphoblasts | Reticular Cells | Plasmocytes | Macrophages | Neutrophils | Eosinophils |
|---|---|---|---|---|---|---|---|
| Al2О3-NP | 85.33 ± 2.04 * | 2.67 ± 0.93 | 1.33 ± 0.66 | 3.33 ± 1.04 | 2.67 ± 0.93 | 1.33 ± 0.66 | 3.33 ± 1.04 |
| TiО2-NP | 85.33 ± 2.04 * | 2.67 ± 0.93 | 1.67 ± 0.74 | 3.33 ± 1.04 | 4.00 ± 1.13 | 1.33 ± 0.66 | 1.67 ± 0.74 |
| SiО2-NP | 74.67 ± 2.51 * | 3.00 ± 0.98 | 1.33 ± 0.66 | 9.00 ± 1.65 * | 3.33 ± 1.04 | 0.33 ± 0.33 | 8.33 ± 1.60 * |
| Al2О3-NP + TiО2-NP | 82.00 ± 2.72 * | 1.50 ± 0.86 | 1.50 ± 0.86 | 6.00 ± 1.68 * | 3.50 ± 1.30 | 1.50 ± 0.86 | 4.00 ± 1.39 |
| Al2О3 + SiО2-NP | 82.89 ± 2.18 *, + | 1.34 ± 0.67 | 0.67 ± 0.47 | 3.02 ± 0.99 + | 7.05 ± 1.48 *, @, + | 1.34 ± 0.67 | 3.69 ± 1.09 + |
| TiО2 + SiО2-NP | 81.40 ± 2.24 *, + | 1.66 ± 0.74 | 1.33 ± 0.66 | 3.32 ± 1.03 + | 6.98 ± 1.47 *, + | 1.99 ± 0.81 | 3.32 ± 1.03 + |
| Control | 90.67 ± 1.68 | 1.67 ± 0.74 | 1.00 ± 0.57 | 2.00 ± 0.81 | 1.67 ± 0.74 | 1.33 ± 0.66 | 1.67 ± 0.74 |
The asterisk * denotes values which are statistically significantly different from the control; the sign @ denotes the difference from the group administered TiО2-NP alone; the sign + the difference from the group administered SiО2-NP alone (p < 0.05 by ANOVA test).
Some Cytological Characteristics of Spleen Tissue Imprints as a Percentage of Total Cell Count in Rats after Subchronic Exposure to Al2O3-NP, TiO2-NP and SiO2-NP Individually or in Binary Combinations (x ± s.e.).
| Factor | Lymphocytes | Lymphoblasts | Reticular Cells | Plasmocytes | Macrophages | Neutrophils | Eosinophils |
|---|---|---|---|---|---|---|---|
| Al2О3-NP | 76.00 ± 2.47 * | 1.00 ± 0.57 | 1.00 ± 0.57 | 3.00 ± 0.98 | 5.00 ± 1.26 | 7.00 ± 1.47 * | 7.00 ± 1.47 |
| TiО2-NP | 75.08 ± 2.49 * | 0.66 ± 0.47 | 0.66 ± 0.47 | 1.66 ± 0.74 | 4.65 ± 1.21 | 7.64 ± 1.53 * | 9.63 ± 1.70 * |
| SiО2-NP | 78.67 ± 2.37 * | 0.33 ± 0.33 | 1.00 ± 0.57 | 1.00 ± 0.57 | 3.67 ± 1.09 | 5.67 ± 1.33 | 9.67 ± 1.71 * |
| Al2О3-NP + TiО2-NP | 82.67 ± 2.19 +, @ | 1.00 ± 0.57 | 0.67 ± 0.47 | 1.00 ± 0.57 | 3.67 ± 1.09 | 4.00 ± 1.13 | 7.00 ± 1.47 |
| Al2О3 + SiО2-NP | 79.33 ± 2.34 * | 0.33 ± 0.33 | 0.67 ± 0.47 | 1.00 ± 0.57 | 4.67 ± 1.22 | 8.33 ± 1.60 * | 5.67 ± 1.33 |
| TiО2 + SiО2-NP | 78.67 ± 2.37 * | 1.00 ± 0.57 | 0.67 ± 0.47 | 1.33 ± 0.66 | 2.33 ± 0.87 | 8.33 ± 1.60 * | 7.67 ± 1.54 * |
| Control | 87.00 ± 1.94 | 0.67 ± 0.47 | 1.33 ± 0.66 | 1.67 ± 0.74 | 3.00 ± 0.98 | 2.67 ± 0.93 | 3.67 ± 1.09 |
The asterisk * denotes values which are statistically significantly different from the control; the sign @ denotes the difference from the group administered TiО2-NP alone; the sign + the difference from the group administered Al2О3-NP alone (p < 0.05 by ANOVA test).
Increase in the Coefficient of Genomic DNA Fragmentation (Cfr) (as per RAPD Test) of Nucleated Blood Cells in Rats after 18 (during 6 Weeks) Repeated Intraperitoneal Injections of Suspensions of Various МеO-NPs Individually and in Binary or Ternary Combination (x ± s.e.).
| MeO-NPs to Which Rats Were Exposed | Cfr |
|---|---|
| Аl2О3-NP | 0.4470 + 0.0038 *, +, х |
| TiО2-NP | 0.4328 + 0.00548 * |
| SiО2-NP | 0.4288 + 0.0061 * |
| Al2О3-NP + TiО2-NP | 0.5416 + 0.0046 *, @ |
| Al2О3-NP + SiО2-NP | 0.4872 + 0.0041 *, х, @ |
| TiО2-NP + SiО2-NP | 0.4391 + 0.0061 *, +, х |
| Al2О3-NP + TiО2-NP + SiО2-NP (half doses) | 0.4849 + 0.0068 *, +, х, @ |
| Al2О3-NP + TiО2-NP + SiО2-NP (full doses) | 0.6430 + 0.0189 *, +, х, @ |
| Al2О3-NP + TiО2-NP + SiО2-NP + BPC | 0.4742 + 0.0067 *, +, х, @ |
| BPC | 0.4143 + 0.0047 |
| Control | 0.4023 + 0.0064 |
The signs denote values differing statistically significantly (p < 0.05 by ANOVA test) as follows: * from the control value, + from the value under exposure to TiО2-NP, х from the value under exposure to SiО2-NP, @ from the value under exposure to Аl2О3-NP. Also, there is a statistically significant difference between the groups administered the ternary MеO-NP combination in full and half doses, and in full dose and in the same dose with background administration of the BPC.
Figure 9Isoboles of binary combined genotoxicity assessed by an increase in nucleated blood cell DNA fragmentation coefficient. (А) in the absence of a third factor under exposure to: (а) SiO2-NP + TiO2-NP (subadditivity); (b) SiO2-NP + Al2O3-NP (additivity); (c) TiO2-NP + Al2O3-NP (superadditivity). (B) with background administration of a third component: (d) Al2O3-NP to SiO2-NP + TiO2-NP (additivity); (e) TiO2-NP to SiO2-NP + Al2O3-NP (single-factor action with transformation into additivity); (f) SiO2-NP to ТiO2-NP + Al2O3-NP (superadditivity). The axes represent corresponding МеО-NPs in mg per rat; the numbers at the isobole denote the dimensionless quantity Cfr.
Figure 10(a) Kidney of a control rat (proximal convoluted tubules with an intact brush border); (b) Kidney of a rat exposed to the ternary MeO-NP combination (marked degenerative and necrobiotic changes in tubular epithelial cells up to their disappearance; partial destruction of the brush border); (c) Kidney of a rat exposed to the same combination against background administration of the BPC. Periodic Acid Shiff (PAS) stain, magnification 400×.
Figure 11SEM images of (a) Al2O3; (b) TiO2 and (c) SiO2 nanoparticles in the suspensions prepared for this animal experiment.
Figure 12Size distribution functions obtained by statistical processing of SEM images of (a) Al2O3-NP; (b) TiO2-NP and (c) SiO2-NP. Arithmetic mean NP diameters (±s.d.) are shown within each panel.
Doses and Mode of Administration of the Bioprotectors Tested in Our Experiment.
| Bioprotectors | Estimated Dosage and Mode of Administration |
|---|---|
| Apple pectin | 1 g/kg (added to the fodder) |
| Sodium glutamate | 160 mg per rat (as a 1.5% drink instead of water) |
| Glycine | 12 mg per rat (added to the food) |
| 30 mg per rat (added to the food) | |
| Vitamin C | 4.4 mg per rat (added to the food) |
| Vitamin E | 0.84 mg per rat (added to the food) |
| Selenium | 4.0 mcg per rat (added to the food) |
| Commercial fish oil rich in vitamin A and omega 3 PUFA | 1 drop per rat (sublingually) |
| Potassium iodide | 4.0 mcg per rat (added to the food) |
| Calcium carbonate | 160 mg per rat (added to the food) |